Nicole Quinn, MD
Obstetrics & Gynecology · Fayetteville, GANPI 1932464617
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.9% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $471 and has fallen 63.9% since, to $170 in 2025.
Across 104 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$363
- AbbVie$335
- Therapeuticsmd, Inc.$128
- Sumitomo Pharma America, Inc.$115
- Exeltis, USA Inc.$100
- Mayne Pharma Commercial LLC$99
- plus $803 from 22 others
What the payments were for
- Food & beverage$1,84395%
- Education$1005%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 15 | $363 |
| AbbVie(2 entities) | 22 | $335 |
| Therapeuticsmd, Inc. | 7 | $128 |
| Sumitomo Pharma America, Inc. | 7 | $115 |
| Exeltis, USA Inc. | 6 | $100 |
| Mayne Pharma Commercial LLC | 6 | $99 |
| Hologic Sales And Service, LLC | 4 | $85 |
| Aspira Women's Health Inc | 1 | $82 |
| Pfizer | 3 | $63 |
| Minerva Surgical, Inc | 3 | $59 |
| Mylan Pharmaceuticals Inc. | 4 | $55 |
| Avion Pharmaceuticals | 4 | $53 |
| Boston Scientific | 2 | $49 |
| Daiichi Sankyo Inc. | 3 | $48 |
| Roche Diagnostics Corporation | 2 | $38 |
| Meditrina | 2 | $36 |
| Coopersurgical, Inc. | 2 | $33 |
| Biogen | 1 | $24 |
| Bayer | 1 | $23 |
| Agile Therapeutics, Inc. | 1 | $21 |
| Millicent US Inc | 1 | $20 |
| Optumhealth Care Solutions, LLC | 1 | $20 |
| Baxter Healthcare | 1 | $20 |
| Evofem Biosciences, Inc. | 1 | $18 |
| Scynexis, Inc. | 1 | $15 |
| Acessa Health Inc. | 1 | $15 |
| GSK | 1 | $14 |
| Medtronic | 1 | $12 |
How this compares
$1,943 in reported general payments places this provider in the 70th percentile of 1,324 obstetrics & gynecology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EstraceEstradiol | 16 | $3,360 |
| Estradiol | 56 | $2,624 |
| ProgesteroneProgesterone, Micronized | 12 | $258 |
| Oxybutynin Chloride ErOxybutynin Chloride | 23 | $248 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $201 |
| Fluconazole | 16 | $56 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Fayetteville
- Matthew RalstenFayetteville$64K
- Elizabeth KillebrewFayetteville$12K
- Edmund KimLawrenceville$628K
- Jacquelin WaltersDuluth$147K
- Nicole SparksJohns Creek$121K
- Lethenia BakerThomaston$111K
- Renee AllenAtlanta$74K
- Murray FreedmanAugusta$48K
- Tosha Rogers-JonesAtlanta$46K
- Teresa ByrdMarietta$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.